Literature DB >> 19687341

Referral, receipt, and completion of chemotherapy in patients with early-stage breast cancer older than 65 years and at high risk of breast cancer recurrence.

Diana S M Buist1, Jessica Chubak, Marianne Prout, Marianne Ulcickas Yood, Jaclyn L F Bosco, Soe Soe Thwin, Heather Taffet Gold, Cynthia Owusu, Terry S Field, Virginia P Quinn, Feifei Wei, Rebecca A Silliman.   

Abstract

PURPOSE: Some women with early-stage breast cancer are at higher risk of recurrence and can benefit from chemotherapy. We describe patterns of referral, receipt, and completion of chemotherapy among older women at high risk of recurrence. PATIENTS AND METHODS: A total of 2,124 women age 65 years or older who were diagnosed with early-stage breast cancer between 1990 and 1994 and 1996 to 1999 were included; 1,090 of these were at high risk of recurrence. We reviewed medical records to categorize chemotherapy outcomes as follows: did not discuss or were not referred to a medical oncologist (n = 133); discussed and/or referred to a medical oncologist but received no chemotherapy (n = 742); received an incomplete chemotherapy course (n = 29), or received a completed chemotherapy course (n = 186).
RESULTS: Overall, 19.7% of high-risk women received any chemotherapy, and 86.5% of these women completed their chemotherapy courses. Just greater than 10% of high-risk women did not have a discussion about chemotherapy as part of breast cancer treatment documented in the medical record; these women also received fewer diagnostic assessments of their initial tumors.
CONCLUSION: Individuals who receive chemotherapy for early-stage breast cancer are a select subgroup of patients at high risk of recurrence. This study identifies characteristics of women who were referred for and who received chemotherapy, and this study plays an important role in understanding generalizability of studies that examine chemotherapy treatment effectiveness. Outcomes after breast cancer could continue to be improved with increased receipt of chemotherapy among older women at high risk of breast cancer recurrence.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19687341      PMCID: PMC2754903          DOI: 10.1200/JCO.2008.18.3459

Source DB:  PubMed          Journal:  J Clin Oncol        ISSN: 0732-183X            Impact factor:   44.544


  21 in total

Review 1.  Beyond randomized controlled trials: a critical comparison of trials with nonrandomized studies.

Authors:  Henrik Toft Sørensen; Timothy L Lash; Kenneth J Rothman
Journal:  Hepatology       Date:  2006-11       Impact factor: 17.425

2.  A new method of classifying prognostic comorbidity in longitudinal studies: development and validation.

Authors:  M E Charlson; P Pompei; K L Ales; C R MacKenzie
Journal:  J Chronic Dis       Date:  1987

3.  Recurrences and second primary breast cancers in older women with initial early-stage disease.

Authors:  Ann M Geiger; Soe Soe Thwin; Timothy L Lash; Diana S M Buist; Marianne N Prout; Feifei Wei; Terry S Field; Marianne Ulcickas Yood; Floyd J Frost; Shelley M Enger; Rebecca A Silliman
Journal:  Cancer       Date:  2007-03-01       Impact factor: 6.860

Review 4.  Early stage breast cancer.

Authors: 
Journal:  Consens Statement       Date:  1990 Jun 18-21

5.  Use and outcomes of adjuvant chemotherapy in older women with breast cancer.

Authors:  Sharon H Giordano; Zhigang Duan; Yong-Fang Kuo; Gabriel N Hortobagyi; James S Goodwin
Journal:  J Clin Oncol       Date:  2006-06-20       Impact factor: 44.544

6.  Adjuvant chemotherapy and survival in older women with hormone receptor-negative breast cancer: assessing outcome in a population-based, observational cohort.

Authors:  Elena B Elkin; Arti Hurria; Nandita Mitra; Deborah Schrag; Katherine S Panageas
Journal:  J Clin Oncol       Date:  2006-06-20       Impact factor: 44.544

7.  Breast cancer treatment of older women in integrated health care settings.

Authors:  Shelley M Enger; Soe Soe Thwin; Diana S M Buist; Terry Field; Floyd Frost; Ann M Geiger; Timothy L Lash; Marianne Prout; Marianne Ulcickas Yood; Feifei Wei; Rebecca A Silliman
Journal:  J Clin Oncol       Date:  2006-09-20       Impact factor: 44.544

8.  Mortality impact of less-than-standard therapy in older breast cancer patients.

Authors:  Marianne Ulcickas Yood; Cynthia Owusu; Diana S M Buist; Ann M Geiger; Terry S Field; Soe Soe Thwin; Timothy L Lash; Marianne N Prout; Feifei Wei; Virginia P Quinn; Floyd J Frost; Rebecca A Silliman
Journal:  J Am Coll Surg       Date:  2007-10-03       Impact factor: 6.113

9.  Community-based use of chemotherapy and hormonal therapy for early-stage breast cancer: 1987-2000.

Authors:  Linda C Harlan; Limin X Clegg; Jeffrey Abrams; Jennifer L Stevens; Rachel Ballard-Barbash
Journal:  J Clin Oncol       Date:  2006-02-20       Impact factor: 44.544

10.  Participation in cancer clinical trials: race-, sex-, and age-based disparities.

Authors:  Vivek H Murthy; Harlan M Krumholz; Cary P Gross
Journal:  JAMA       Date:  2004-06-09       Impact factor: 56.272

View more
  15 in total

1.  Black-white differences in receipt and completion of adjuvant chemotherapy among breast cancer patients in a rural region of the US.

Authors:  Joseph Lipscomb; Theresa W Gillespie; Michael Goodman; Lisa C Richardson; Lori A Pollack; A Blythe Ryerson; Kevin C Ward
Journal:  Breast Cancer Res Treat       Date:  2012-01-26       Impact factor: 4.872

2.  Long-term surveillance mammography and mortality in older women with a history of early stage invasive breast cancer.

Authors:  Diana S M Buist; Jaclyn L F Bosco; Rebecca A Silliman; Heather Taffet Gold; Terry Field; Marianne Ulcickas Yood; Virginia P Quinn; Marianne Prout; Timothy L Lash
Journal:  Breast Cancer Res Treat       Date:  2013-10-11       Impact factor: 4.872

3.  Occupational type affects the receipt of breast cancer adjuvant chemotherapy in China.

Authors:  Zhengzhi Zhu; Qiang Huo; Shengying Wang; Qifeng Yang
Journal:  Oncol Lett       Date:  2015-08-04       Impact factor: 2.967

4.  Using natural language processing to improve efficiency of manual chart abstraction in research: the case of breast cancer recurrence.

Authors:  David S Carrell; Scott Halgrim; Diem-Thy Tran; Diana S M Buist; Jessica Chubak; Wendy W Chapman; Guergana Savova
Journal:  Am J Epidemiol       Date:  2014-01-30       Impact factor: 4.897

5.  Treatment of ductal carcinoma in situ among patients cared for in large integrated health plans.

Authors:  Reina Haque; Ninah S Achacoso; Suzanne W Fletcher; Larissa Nekhlyudov; Laura C Collins; Stuart J Schnitt; Charles P Quesenberry; Laurel A Habel
Journal:  Am J Manag Care       Date:  2010-05       Impact factor: 2.229

6.  Validity of eight integrated healthcare delivery organizations' administrative clinical data to capture breast cancer chemotherapy exposure.

Authors:  Thomas Delate; Erin J Aiello Bowles; Roy Pardee; Robert D Wellman; Laurel A Habel; Marianne Ulcickas Yood; Larissa Nekhlyudov; Katrina A Goddard; Robert L Davis; Catherine A McCarty; Adedayo A Onitilo; Heather Spencer Feigelson; Jared Freml; Edward Wagner
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2012-02-15       Impact factor: 4.254

7.  Variations in Guideline-Concordant Breast Cancer Adjuvant Therapy in Rural Georgia.

Authors:  Gery P Guy; Joseph Lipscomb; Theresa W Gillespie; Michael Goodman; Lisa C Richardson; Kevin C Ward
Journal:  Health Serv Res       Date:  2014-12-10       Impact factor: 3.402

8.  Body mass index, tumor characteristics, and prognosis following diagnosis of early-stage breast cancer in a mammographically screened population.

Authors:  Aruna Kamineni; Melissa L Anderson; Emily White; Stephen H Taplin; Peggy Porter; Rachel Ballard-Barbash; Kathleen Malone; Diana S M Buist
Journal:  Cancer Causes Control       Date:  2012-12-07       Impact factor: 2.506

9.  Adjuvant chemotherapy for breast cancer in patients with schizophrenia.

Authors:  Mark Hwang; Mishel Farasatpour; Campbell D Williams; Julie A Margenthaler; Katherine S Virgo; Frank E Johnson
Journal:  Oncol Lett       Date:  2012-01-09       Impact factor: 2.967

10.  Racial and ethnic disparities in 21-gene recurrence scores, chemotherapy, and survival among women with hormone receptor-positive, node-negative breast cancer.

Authors:  Yunan Han; Zhi-Feng Miao; Min Lian; Lindsay L Peterson; Graham A Colditz; Ying Liu
Journal:  Breast Cancer Res Treat       Date:  2020-09-14       Impact factor: 4.872

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.